One important metric to look for in a stock is an 80 or higher Relative Strength Rating. KrystalBiotech stock now clears that threshold, with a jump from 73 to 87 Monday.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD's proprietary rating measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the best stocks typically have an RS Rating north of 80 as they launch their biggest climbs.
See How IBD Helps You Make More Money In Stocks
Is Krystal Biotech Stock A Buy?
Krystal Biotech stock has dipped below its 200-day moving average in recent weeks and currently out of a proper entry point. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line and wait for the market to change directions to confirmed uptrend.
The biotech firm reported -168% earnings growth last quarter, while sales growth came in at 0%.
Krystal Biotech stock earns the No. 140 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls and Regeneron Pharmaceutical are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
